Nevro Corp. (NVRO) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Angie McCabe - Vice President, Investor Relations & Corporate Communications Kevin Thornal - CEO and ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. (NYSE: NVRO) to Globus Medical for $5.85 per share is ...

Nevro Corp. (NYSE: NVRO) Q1 2024 Earnings Call Transcript May 8, 2024 Nevro Corp. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Based on Nevro Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $104.16 million and a GAAP net loss of $19.58 million. In comparison ...

Nevro Corp (NYSE:NVRO), a medical device company specializing in spinal cord stimulation (SCS) technology for chronic pain treatment, has recently undergone significant changes in its market ...

Nevro Corp. NVRO is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) edge. The optimism led by a solid first-quarter 2024 performance and continued ...

August 20, 2024 — 01:04 pm EDT Written by Zacks Equity Research for Zacks -> Nevro Corp. NVRO is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) edge.

Nevro Corp.'s shares hit fresh lows after revenue guidance reset, reflecting stagnant growth and substantial losses. Learn more about NVRO stock here.

Nevro Corp. common stock ceased trading on the New York Stock Exchange prior to the open of the market on April 3, 2025.